Breast cancer claims approximately 670,000 lives annually, making it a significant health concern worldwide. According to the World Health Organization (WHO), breast cancer was the most prevalent cancer among women in 157 out of 185 countries in 2022. With over 2 million women diagnosed each year, early detection and targeted treatments are crucial for combating this deadly disease. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for early-stage breast cancer treatment in combination with hormone therapy. This approval provides a valuable option for patients worried about cancer recurrence. Kisqali works as a selective cyclin-dependent kinase inhibitor, targeting proteins that promote cancer cell growth and division. It will be administered orally, recommended for a three-week cycle with a one-week break, over a three-year period. The medication can be taken with or without food, with a daily dose of 400 mg.Kisqali ed.: Potential Side Effects

Common side effects of Kisqali medication include low white blood cell count, known as neutropenia, which can hinder the body's ability to fight off infections. Kisqali may also lead to liver complications and interstitial lung disease/pneumonitis.

Breast Cancer: Warning Signs Not to Overlook